Professional
Added to YB: 2024-07-25
Pitch date: 2024-07-13
ILMN [bullish]
Illumina, Inc.
+16.16%
current return
Author Info
No bio for this author
Company Info
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
Market Cap
$18.4B
Pitch Price
$116.11
Price Target
N/A
Dividend
N/A
EV/EBITDA
15.81
P/E
27.05
EV/Sales
4.60
Sector
Life Sciences Tools and Services
Category
turnaround
Ensemble Capital Management Portfolio Holding: Illumina, Inc.
ILMN: 80-90% global sequencing leader. NovaSeq X+ cuts genome cost to $200, enabling new apps. AI complements, accelerating discoveries. GRAIL acquisition for MCED screening faced regulatory issues. Core biz slowdown from post-COVID, capital markets, product transition. New CEO divesting GRAIL, focusing on profit improvement. Undervalued with strong competitive position & growth potential from clinical apps.
Read full article (4 min)